Retatrutide Side Effects vs Tirzepatide and Semaglutide Because retatrutide activates three receptors (GLP-1, GIP, and glucagon) rather than the two targeted by tirzepatide or the one targeted by semaglutide, it tends to produce more gastrointestinal side effects than either drug
The SUSTAIN-6 cardiovascular outcomes trial established that semaglutide also reduces the risk of major adverse cardiovascular events (MACE) by 26% relative to placebo in high-risk patients a finding that fundamentally changed the treatment landscape for metabolic disease
Verified review - view original Received the product quickly
Outcomes commonly tracked included low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, fasting plasma glucose, insulin, systolic and diastolic blood pressure, C-reactive protein (CRP, an inflammation biomarker), and salivary immunoglobulin A (IgA, an immune biomarker)